Alimta

...Kalypsys Announces Key Appointment Yahoo!

My Yahoo!

Mail Welcome, Guest [Sign Out, My Account] Finance Home - Help Welcome [Sign In] To track stocks & more, Register Financial NewsEnter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup Press ReleaseSource: Kalypsys Kalypsys Announces Key AppointmentWednesday July 20, 8:00 am ET - Dr.

August Watanabe Named Chairman of the Board of Directors - SAN DIEGO, July 20 /PRNewswire/ - Kalypsys, a privately owned San Diego-based drug discovery and development company, announced today the appointment of August Watanabe, M.D., as non-executive Chairman of its Board of Directors.Dr.

Watanabe was appointed to the Kalypsys Board of Directors on March 15, 2005.

He served as a senior executive at Eli Lilly Company for 13 years beginning in 1990.

From 1994 until his retirement in 2003, he held the positions of Executive Vice President of science and technology, President of Lilly Research Laboratories and was a member of the company's Board of Directors.

During his leadership of R&D at Lilly, the company became recognized as having one of the strongest pipelines of new compounds in the industry, including the recently launched drugs Watanabe was a faculty member of the Department of Internal Medicine at Indiana University School of Medicine for 18 years and was Chairman of the Department of Internal Medici...

... i-Newswire.com - Press Release And News Distribution - Thoracic Cancer Patients Find New Hope with combination.

If you...

... Thoracic Cancer Patients Find New Hope with "Before Vogelzang, MD, director of the Nevada Cancer Institute in Las Vegas.

"At 18 months, there is still a statistically significant difference in survival, which demonstrates patients are living longer when treated with this If you look out further to 24 months, 22 percent of patients treated with